The Festival of Biologics USA will begin with an afternoon of workshops, taking place on the 3rd March from 1pm, finishing at 4pm .
This workshops and panels will be on challenging topics across the antibodies, immunotherapy, clinical trials and biosimilar industries, with an additional session being run in conjunction with SDCPI, the San Diego Centre of Precision Immunotherapy. 

Across the afternoon, there will be 16 workshops, as well as the SDCPI seminars, run by leading experts in their field, and are available to all fully registered attendees, speakers, sponsors and exhibitors.



13:00 - 13:45 AI for antibody drug discovery and development

  • An overview of how AI is currently used for in silico antibody discovery and development
  • Real life examples of how this is currently used, with challenges and case studies
  • Workshop on how AI can be implemented into the antibody industry
Stanley Krystek , Senior Principal Scientist, Bristol Myers-Squibb

Dana Filoti , Senior Scientist, NBE Analytical R&D, AbbVie
Sandeep Kumar , Senior Research Fellow, (Biotherapeutics) and Group Leader, Boehringer Ingelheim
Qing Chai , Principle Scientist, Lilly Biotechnology Center

14:30 - 15:15 Women in Science – panel discussion

  • Experiences that have influenced thinking around gender in the workplace
  • How companies are promoting diversity in the workplace
  • How can we advocate change, successes and challenges?
  • How can male advocates help?

Marilyn Kehry
, Vice President, Cell and Functional Biology, AnaptysBio
Jill O’Donnell-Tormey , CEO and Director of Scientific Affairs, Cancer Research Institute
Stephen Demarest , Senior Research Fellow, Protein and Antibody Engineering, Lilly Biotechnology Center
Line Ledsgaard
, Research Assistant, Technical University of Denmark

15:15 - 16:00 Investment in antibody therapeutics panel

  • Panel session lead by senior investors, actively investing within the biologics industry
  • What do investors look out for in start-ups?
  • What are the current trends for biologics? 
  • Where do we see the industry moving to in the next 5-10 years?
  • How can you gain investment?

Moderated by: Stuart Collinson , Partner, Forward Ventures 
Kevin Johnson , General Partner, Medicxi
Standish Fleming , Managing Member, Owner, Forward Ventures

13:00 - 13:45 Progress and challenges in the design and clinical development of microbial therapies

  • Influence of the gut microbiome on autoimmunity
  • Gut microbes and immunotherapy responses
  • Leaky Gut Syndrome in autoimmune diseases – a potential target for therapy
  • Success in a probiotic trial in Irritable Bowel Syndrome – a new therapeutic perspective targeting the dysbiosis and beyond
  • Designing multi-targeted bacterial therapy – what tools do we need?

Shahram Lavasani , CEO, ImmuneBiotech

14:00 – 16:00 A series of short presentations by members of the San Diego Center for Precision Immunotherapy

Moderated by:  Ezra Cohen , Associate Director, U.C. San Diego Moores Cancer Center
Other SDCPI speakers TBC





13:00 - 13:45 Partnering with patient advocacy organizations to bring the patient voice into the development of clinical trials

  • Strategies for determining which advocacy organizations to partner with
  • Tactics for bringing in the patient voice early and often
  • Getting buy-in from Sr. leadership on the importance of advocacy relationships and inclusion of patient voice

Beth Zaharoff , Director, patient Focused Drug Development, Tesaro
Sheryl Lapidus , Director, Corporate Affairs and Patient Advocacy, Tesaro




13:00 - 13:45 Analytics and innovation  - ​The role it plays in the current and future state of biosimilars 

Julio Baez , Former Head of Technology, Cipla BioTec

13:45 - 14:30 Panel Discussion: How can we sustain the value proposition of biosimilars in the future as an industry?


Chair:  Ian Henshaw , Global Head of Biogen’s Biosimilars Unit, Biogen
Alain Vertès , Managing Director, NxR Biotechnologies GmbH

14:30 - 15:15 Implementing modern Cell engineering and Process development approaches for affordable and sustainable biosimilar manufacturing

  • General Overview of Biosimilars/ Biologics and opportunities for the Biopharma players
  • Implementation of Gene editing tools CRISPR and TALENS for cell line engineering  and  production improvement
  • Modern approaches for high producer cell line and robust upstream process development
  • Use of cutting edge technologies to improve biosimilar development and manufacturing 
  • Factors influences protein expression and critical quality attributes including glycosylation of monoclonal antibodies 
  • mAb glycosylation and its overall Impact on biosimilarity and product performance
  • Case studies on titer and  quality improvement at clone and process level for affordable biosimilar development

Sanjeev Gupta , General Manager -Advanced Biotech Lab, Ipca Laboratories

14:30 - 15:15 Panel discussion: Clinical trials – do we need them to get biosimilars approved?

  • Clinical trials vs pharmacology studies, what does the current FDA and EU guidance say?
  • Clinical pharmacology studies: efficacy & safety
  • Future possibilities 
  • Q + A with the audience
Gerry Hoehn , Medical Director, Oncology, Teva
Ruediger Jankowsky , Managing Director, Cinfa Biotech




To Sponsor Or Exhibit


Derek Cavanagh
t/ +44 (0)207 092 1297




To Speak


Joan Shutt
t/ +44 (0)207 092 1134




To Register


Tayyab Abbasi
t/ +44 (0)207 092 1210